AtaCor Medical Announces First Patient Treated Globally in its ALARION-EV Pivotal Trial

Trial StartAtalaEV-ICD pulse generatorPositive

AI Analysis

Summary

AtaCor Medical announced the first patient enrolled in its ALARION-EV pivotal trial evaluating the investigational Atala lead with Abbott's EV-ICD pulse generator for treating life-threatening ventricular tachyarrhythmias using a novel parasternal extravascular approach.

Clinical Trial Data

Phase

pivotal

Importance:5/10

Sentiment:

0.50

trial initiationextravascular ICDventricular arrhythmiasmedical devicepartnership

Related Companies

$ABT

Read the original article

Published by PR Newswire Clinical Trials on July 7, 2026 12:03 PM

Read Original